Key points are not available for this paper at this time.
진행성 흑색종 환자, 특히 ipilimumab 치료 중 질병이 진행된 환자들을 대상으로 한 Lambrolizumab 치료는 주로 1 또는 2등급 독성 효과와 함께 높은 지속적 종양 퇴축율을 나타냈다. (Merck Sharp and Dohme 후원; ClinicalTrials.gov 번호 NCT01295827.)
Building similarity graph...
Analyzing shared references across papers
Loading...
Omid Hamid
Caroline Robert
Adil Daud
New England Journal of Medicine
University of Pennsylvania
University of California, Los Angeles
University of California, San Francisco
Building similarity graph...
Analyzing shared references across papers
Loading...
Hamid 등(Sun,)이 이 문제를 연구했다.
www.synapsesocial.com/papers/69dbf07cc34c3c3eb46842c1 — DOI: https://doi.org/10.1056/nejmoa1305133
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: